GBA
ATHE

Garrison Bradford & Associates’s Alterity Therapeutics ATHE Stock Holding History

Garrison Bradford & Associates’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,555
Closed -$70K – 89
2016
Q3 		$70K Buy
+1,555
New +$77.5K 0.07% 83
2016
Q2 		– Sell
-1,656
Closed -$47K – 90
2016
Q1 		$47K Hold
1,656
– – 0.05% 70
2015
Q4 		$72K Sell
1,656
-166
-9% -$8.44K 0.08% 75
2015
Q3 		$98K Hold
1,822
– – 0.11% 81
2015
Q2 		$128K Hold
1,822
– – 0.13% 89
2015
Q1 		$122K Sell
1,822
-9
-0.5% -$718 0.11% 93
2014
Q4 		$180K Sell
1,831
-275
-13% -$29.7K 0.16% 96
2014
Q3 		$270K Sell
2,106
-50
-2% -$6.69K 0.27% 75
2014
Q2 		$293K Sell
2,156
-91
-4% -$10.4K 0.27% 76
2014
Q1 		$378K Buy
2,247
+109
+5% +$60.2K 0.36% 64
2013
Q4 		$899K Buy
2,138
+458
+27% +$137K 0.85% 28
2013
Q3 		$414K Buy
1,680
+250
+17% +$57.4K 0.42% 53
2013
Q2 		$199K Buy
+1,430
New +$194K 0.21% 85

Other funds holding ATHE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
MFS
MSI Financial Services Springfield, Massachusetts $3.07B AUM 10.22% 1-Year Est. Return

Garrison Bradford & Associates's ATHE Position: Q4 2016 in Review

Garrison Bradford & Associates sold out of Alterity Therapeutics (ATHE) in Q4 2016, closing a stake of 1,555 shares — an estimated $70K sold.

Garrison Bradford & Associates first reported a position in ATHE in Q2 2013 and held it in 13 quarters. The position peaked at $899K in Q4 2013. 17 funds tracked by Wall St. Rank hold ATHE as of Q4 2016.

  • Garrison Bradford & Associates reported no remaining Alterity Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Garrison Bradford & Associates sold 1,555 Alterity Therapeutics shares in Q4 2016, an estimated $70K.
  • Garrison Bradford & Associates first reported a position in Alterity Therapeutics in Q2 2013 and held it in 13 quarters.
  • Garrison Bradford & Associates's Alterity Therapeutics position peaked at $899K in Q4 2013.
  • 17 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q4 2016.

Based on Garrison Bradford & Associates's 13F filing for Q4 2016, filed 31 Jan 2017.